Safety and Performance Study of the FAST-FIX FLEX System for Meniscal Repairs and Meniscal Transplantations
NCT ID: NCT04903106
Last Updated: 2024-12-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
63 participants
OBSERVATIONAL
2022-01-20
2024-11-26
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The objectives of the study are to assess the clinical success rate of both clinical indications (meniscal repair and meniscal allograft transplantations) and the performance and safety of the FAST-FIX FLEX meniscal repair system.
The sample size for this study is precision-based and not based on statistical power considerations. Thus, no formal statistical hypothesis is formulated. The sample size for this study is determined based on the feasibility of recruitment, enrolment and follow-up considerations.
The primary endpoint upon which the sample size is determined is defined by the rate of reoperation after at 12 months.
Additionally, secondary endpoints in this study assess success rate, meniscus healing and clinical performance of Patient Reported Outcomes (PRO) for meniscal repair and meniscal allograft transplantations.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Meniscal Tear
Subject requires a meniscus repair concerning the red-red or red-white zones for acute or chronic 1-, 2- or 3-segment lesions, with or without associated anterior cruciate ligament (ACL) reconstruction.
FAST-FIX FLEX Meniscal Repair System
Standard of care surgery in which the meniscus is repaired using FAST-FIX FLEX device.
Meniscal Insufficiency
Subject requires a MAT for symptomatic meniscal insufficiency (load related pain and swelling in the compartment undergoing meniscectomy) for which conservative treatment has failed.
FAST-FIX FLEX Meniscal Repair System
Standard of care surgery in which the FASTFIX FLEX device is used during the meniscal allograft transplantation procedure.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
FAST-FIX FLEX Meniscal Repair System
Standard of care surgery in which the meniscus is repaired using FAST-FIX FLEX device.
FAST-FIX FLEX Meniscal Repair System
Standard of care surgery in which the FASTFIX FLEX device is used during the meniscal allograft transplantation procedure.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Subject is between sixteen (16) and seventy (70) years of age, inclusive at the time of screening;
3. Subject is willing and able to participate in required follow-up visits and is able to complete study activities;
4. Subject requires a meniscal repair;
5. Subject is suitable to participate in the study in the opinion of the Investigator;
6. Subject requires a meniscus repair concerning the red-red or red-white zones for acute or chronic 1-, 2- or 3-segment lesions, with or without associated anterior cruciate ligament (ACL) reconstruction.
1. Subject provides written informed consent for study participation using an independent ethical committee (IEC) / institutional review board (IRB) approved consent form;
2. Subject is between sixteen (16) and seventy (70) years of age, inclusive at the time of screening;
3. Subject is willing and able to participate in required follow-up visits and is able to complete study activities;
4. Subject requires a meniscal allograft transplantation;
5. Subject is suitable to participate in the study in the opinion of the Investigator.
6. Subject requires a MAT for symptomatic meniscal insufficiency (load-related pain and swelling in the compartment post meniscectomy) for which conservative treatment has failed, with or without cartilage repair or restoration (including ACL reconstruction or repair).
Exclusion Criteria
2. Enrolled in the treatment period of another clinical trial within thirty (30) days of operative visit, or during the study;
3. Women who are pregnant or nursing;
4. Any subject that meets the definition of a Vulnerable Subject per ISO 14155 Section 3.55 (except for subjects aged sixteen (16) or seventeen (17) years of age with consent from their legally authorized representative);
5. Subjects with a history of poor compliance with medical treatment, physical therapy (PT)/rehabilitation, or clinical study participation;
6. Patients with irreparable meniscal tears (i.e. multiple tears);
7. Subjects with full thickness cartilage defects greater than 10mm in diameter and/or serious defects;
8. Patients with concomitant ligament injuries that do not require surgical repair (i.e. ACL with Grade 3 lateral collateral ligament (LCL) injury or medial collateral ligament (MCL) injury);
9. Performance of a significant concomitant procedure, specifically a cartilage repair or restoration (excluding ACL reconstruction or repair, lateral extra-articular tenodesis, anterolateral ligament (ALL) reconstruction) intended as a therapeutic intervention on the study knee;
10. History of ipsilateral knee surgery, septic joint, or fracture;
11. Pathological conditions in the soft tissue that would prevent secure fixation of the device;
12. Physical conditions which would eliminate, or tend to eliminate, adequate anchor support or retard healing;
13. The presence of infection;
14. Conditions which would limit the patient's ability or willingness to restrict activities or follow directions during the healing period;
15. Malalignment: genu varus and genu valgus angles greater than 5° as evaluated by the patient's physician as per their standard of care;
16. Patients who have an Ahlback grade greater than II;
17. Patients with a body mass index larger than 35;
18. Subjects with a medical or physical condition that, in the opinion of the Investigator, would preclude safe subject participation in the study.
1. Contraindications (per the FAST-FIX FLEX IFU) or hypersensitivity to the use of the FAST-FIX FLEX implant material. Where material sensitivity is suspected, appropriate tests should be made and sensitivity ruled out prior to implantation;
2. Enrolled in the treatment period of another clinical trial within thirty (30) days of operative visit, or during the study;
3. Women who are pregnant or nursing;
4. Any subject that meets the definition of a Vulnerable Subject per ISO 14155 Section 3.55 (except for subjects aged sixteen (16) or seventeen (17) years of age with consent from their legally authorized representative);
5. Subjects with a history of poor compliance with medical treatment, physical therapy (PT)/rehabilitation, or clinical study participation;
6. Patients with concomitant ligament injuries that do not require surgical repair (i.e. ACL with Grade 3 lateral collateral ligament (LCL) injury or medial collateral ligament (MCL) injury);
7. Performance of a significant concomitant procedure (excluding ACL reconstruction or repair, lateral extra-articular tenodesis, anterolateral ligament (ALL) reconstruction) intended as a therapeutic intervention on the study knee;
8. History of ipsilateral knee surgery, septic joint, or fracture (excluding MAT indication);
9. Pathological conditions in the soft tissue that would prevent secure fixation of the device;
10. Physical conditions which would eliminate, or tend to eliminate, adequate anchor support or retard healing;
11. The presence of infection;
12. Conditions which would limit the patient's ability or willingness to restrict activities or follow directions during the healing period;
13. Malalignment: genu varus and genu valgus angles greater than 5° as evaluated by the patient's physician as per their standard of care;
14. Patients who have an Ahlback grade greater than II;
15. Patients with a body mass index larger than 35;
16. Subjects with a medical or physical condition that, in the opinion of the Investigator, would preclude safe subject participation in the study.
16 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Smith & Nephew, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Rupali Soeters
Role: STUDY_CHAIR
Smith & Nephew, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rush University Medical Center
Chicago, Illinois, United States
Hospital for Special Surgery
New York, New York, United States
Fremantle Hospital
Fremantle, Western Australia, Australia
Ambroise Paré Clinic
Paris, Neuilly-Sur-Seine, France
Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Foundation Trust
Oswestry, Shropshire, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FAST-FIX FLEX.2020.09
Identifier Type: -
Identifier Source: org_study_id